| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -3.1 | -3.3 |
| EPS (diluted, $ a share) | $-0.21 | $-1.57 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -15.4% |
|---|
10-Q filed with the SEC, NYSE: AIM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
AIM ImmunoTech Inc.: key numbers
- Share price
- $0.1310Close, Nov 16
- Market cap
- $5.23M
- Shares outstanding
- 39.92MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from AIM ImmunoTech Inc.
All →AIM ImmunoTech Investor Presentation
AIM ImmunoTech Inc. has released a new corporate presentation titled 'The Ampligen Opportunity' along with a corresponding press release. The presentation outlines the company's strategic objectives and the clinical potential of its lead drug candidate, Ampligen, particularly in treating pancreatic cancer.
AIM ImmunoTech Debt Financing Update with Streeterville Capital, LLC
AIM ImmunoTech entered into exchange agreements with Streeterville Capital to convert approximately $400,000 of an existing November 2025 promissory note into 1,749,434 shares of common stock. The conversion was executed at an average price of approximately $0.228 per share following prior stockholder approval for the debt satisfaction.
- Counterparty
- Streeterville Capital, LLC